{"preliminary_commentary":{"by_channel":{"youtube":1,"podcast":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"DAWN-303","nct_id":"NCT07522073","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dawn-303-nct07522073. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DAWN-303","arms":[{"description":"INCB161734 at the protocol-defined dose with investigator's choice of chemotherapy (mFOLFIRINOX or GemNabP) in accordance with the protocol-defined requirements.","label":"INCB161734 plus chemotherapy","type":"EXPERIMENTAL"},{"description":"Placebo at the protocol-defined dose with investigator's choice of chemotherapy (mFOLFIRINOX or GemNabP) in accordance with the protocol-defined requirements.","label":"Placebo plus chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Qiagen Manchester Ltd"],"completion_date":{"date":"2029-03-19","type":"ESTIMATED"},"conditions":["Solid Tumors"],"enrollment":{"count":588,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"INCB161734","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Investigator's choice of chemotherapy","otherNames":["mFOLFIRINOX","GemNabP"],"type":"DRUG"}],"last_update":"2026-10-08","lead_sponsor":"Incyte Corporation","official_title":"A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-09-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3 years"},{"measure":"Progression-free survival (PFS) by BICR","timeFrame":"Up to approximately 2 years"},{"measure":"Objective Response by BICR","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2026-04-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT07522073"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dawn-303-nct07522073"}